-

Announcing New Fourier 80 Benchtop FT-NMR Capabilities for Pharmaceutical and Food Analysis Markets

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announces new capabilities for its benchtop Fourier transform (FT) nuclear magnetic resonance (NMR) spectrometer, the Fourier 80, which does not require special lab infrastructure or cryogens, and offers excellent 1H sensitivity of 200:1 for gradient spectroscopy proton probes. A new adjustable temperature option increases experimental flexibility, while new solutions for pharma and food analysis provide improved synthesis and process control, bringing NMR capabilities to more research and analytical laboratories.

The enhanced Fourier 80 now features an Adjustable Temperature (AT) option, expanding its range of applications by enabling sample analysis from 25°C up to 60°C, all compatible with the optional Fourier 80 PAL sample changer.

The new Fourier 80 reaction monitoring solution RxnLab™ for chemical and pharmaceutical labs features temperature-controlled reaction paths to minimize heat loss, optimize process control, and monitor reaction products with the new Fourier 80 flow accessory. Running InsightMR software, the RxnLab brings benchtop FT-NMR to bio- and chemical production with push-button operation for non-NMR experts. For non-flow measurements, the Fourier RxnLab can also use standard 5 mm NMR tubes. The new Fourier 80 GxP Readiness Kit allows full GxP compliance for development and manufacturing labs with 21 CFR part 11 compliance.

“We love the Fourier 80, it has been working 24/7 since it arrived,” states Professor Andre Simpson from the University of Toronto. “What sets it apart is its flexibility to run experiments from our high field NMR systems, including all the pulse programs we have written ourselves. The Fourier 80 revolutionizes what we can do at low field and truly establishes it as a powerful research tool.”

A new Fourier 80 food analysis solution, called NMR Olive Oil-Profiling™ 1.0, delivers authenticity and quality analysis of olive oil, one of the most adulterated food products worldwide. The new Olive Oil-Profiling 1.0 solution is suitable for olive oil bottlers, olive oil testing laboratories, and satellite laboratories. Its companion high-field 400 MHz NMR FoodScreener supports private testing and governmental laboratories in the analysis of multiple or complex food matrices.

Dr. Venita Decker, Bruker’s Product Manager Compact NMR, stated: “These new Fourier 80 capabilities and solutions push the boundaries of benchtop FT-NMR. With the Adjustable Temperature option, analytical chemists can now measure samples, e.g. at 25°C, or 37°C one day, and polymers at 60°C the next. This is particularly useful for reaction monitoring in chemical and pharmaceutical research and QC.”

For more information, visit our Fourier 80 website.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Investor Contact:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media Contact:
Thorsten Thiel, Ph. D.
VP of Group Marketing, Bruker BioSpin
T: +49 (721) 5161–6500
E: pr@bruker.com

Customer Contact:
Dr. Venita Decker
Product Manager Compact NMR (TD/FT)
Bruker BioSpin Group
E: compact.ftnmr@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Investor Contact:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media Contact:
Thorsten Thiel, Ph. D.
VP of Group Marketing, Bruker BioSpin
T: +49 (721) 5161–6500
E: pr@bruker.com

Customer Contact:
Dr. Venita Decker
Product Manager Compact NMR (TD/FT)
Bruker BioSpin Group
E: compact.ftnmr@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026

WASHINGTON--(BUSINESS WIRE)--At ASM Microbe 2026, Bruker Corporation’s (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics. During the ASM 2026 meeting, Bruker showcases the expanded clinical capabilities of the MALDI Biotyper® CA System enabled by...

Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry

SAN DIEGO--(BUSINESS WIRE)--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, sustainable fuels and advanced energy storage. The timsMRMS is an innovative platform that combines Trapped Ion Mobility Spectrometry (TIMS) with extreme-resolution Magnetic Resonance Mass Spectrometry (MRMS), to unravel the complex molecular makeup of challenging fossil fuels and green energy materials. It accomplishes this wit...

Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology

SAN DIEGO--(BUSINESS WIRE)--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the unique timsMRMS system, bringing the power of trapped ion mobility separation to ultra-high-resolution magnetic resonance mass spectrometry (MRMS). A translational oncology research initiative by Prof. Stephan Singer at University Hospital Tübingen enables therapy selection, measuring more than 10,000 proteins in FFPE biopsies to reveal actionable tumor biology when precision genomics is inconclus...
Back to Newsroom